Table 4. Comparison of study design, sample size, triggers and ART procedure in different studies.
Author	Study Design	Participants			Trigger		ART
		Total	Group		Group
			Intervention	Reference	Intervention	Reference
Schachter et al., 2008	Prospective RCT	221	105	106	Triptorelin 0.2mg + hCG 5,000IU	hCG 5,000IU	IVF and IVF-ICSI
Lin et al., 2013	Retrospective Cohort Study	376 (378 cycles)	191	187	Triptorelin 0.2mg + rhCG 250μg	rhCG 250μg	IVF and IVF-ICSI
Decleer et al., 2014	Prospective RCT	120	61	59	Triptorelin 0.2mg + hCG 5,000IU	hCG 5,000IU	IVF-ICSI
Mahajan et al., 2016	Prospective RCT	76	38	38	Leuprolide 1mg + hCG 5,000IU	hCG 10,000IU	IVF-ICSI
Seval et al., 2016	Retrospective Case Control	156	84	72	Leuprolide 0.5mg + rhCG 250μg	rhCG 250μg	IVF and IVF-ICSI
Alleyassin et al., 2018	Prospective RCT	126	63	63	Triptorelin 0.2mg + hCG 5,000IU	hCG 10,000IU	ICSI
Ali et al., 2020	Prospective RCT	160	80	80	Leuprolide 1mg + rhCG 250μg	rhCG 250μg	ICSI
Haas et al., 2020	Prospective RCT	155	77	78	Buserelin 0.5mg + 10,000IU hCG	hCG 10,000IU + Placebo (normal saline)	IVF and IVF-ICSI
Current study	Prospective RCT	100	50	50	Leuprolide 1mg + rhCG 250μg	rhCG 250μg	IVF and IVF-ICSI